Why the study?
Are LEPR Q223R and LEP promoter 2548G/A polymorphisms associated with obesity in patients using atypical antipsychotic medication?
Population
200 male and female patients aged 18-65 years, diagnosed with a psychotic disorder, using an atypical…
Comparison
LEPR Q223R polymorphism and LEP promoter 2548G/A… vs Different genotypes within the same polymorphisms
Design
Cross-sectional
Authors
Loading...
Hypothesis-generating for sex-specific genetic risk of antipsychotic weight gain in females; prospective validation required before clinical use.
Are LEPR Q223R and LEP promoter 2548G/A polymorphisms associated with obesity in patients using atypical antipsychotic medication?
The LEPR Q223R polymorphism is associated with a lower risk of obesity in female patients treated with atypical antipsychotics, highlighting a gender-specific genetic susceptibility to metabolic side effects.
Gregoor et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: